Non-replication of the association between 5HTTLPR and response to psychological therapy for child anxiety disorders

Kathryn J Lester,Susanna Roberts,Robert Keers,Jonathan R I Coleman,Gerome Breen,Chloe C Y Wong,Xiaohui Xu,Kristian Arendt,Judith Blatter-Meunier,Susan Bögels,Peter Cooper,Cathy Creswell,Einar R Heiervang,Chantal Herren,Sanne M Hogendoorn,Jennifer L Hudson,Karen Krause,Heidi J Lyneham,Anna McKinnon,Talia Morris,Maaike H Nauta,Ronald M Rapee,Yasmin Rey,Silvia Schneider,Sophie C Schneider,Wendy K Silverman,Patrick Smith,Mikael Thastum,Kerstin Thirlwall,Polly Waite,Gro Janne Wergeland,Thalia C Eley

DOI: https://doi.org/10.1192/bjp.bp.114.154997

Abstract:Background: We previously reported an association between 5HTTLPR genotype and outcome following cognitive-behavioural therapy (CBT) in child anxiety (Cohort 1). Children homozygous for the low-expression short-allele showed more positive outcomes. Other similar studies have produced mixed results, with most reporting no association between genotype and CBT outcome. Aims: To replicate the association between 5HTTLPR and CBT outcome in child anxiety from the Genes for Treatment study (GxT Cohort 2, n = 829). Method: Logistic and linear mixed effects models were used to examine the relationship between 5HTTLPR and CBT outcomes. Mega-analyses using both cohorts were performed. Results: There was no significant effect of 5HTTLPR on CBT outcomes in Cohort 2. Mega-analyses identified a significant association between 5HTTLPR and remission from all anxiety disorders at follow-up (odds ratio 0.45, P = 0.014), but not primary anxiety disorder outcomes. Conclusions: The association between 5HTTLPR genotype and CBT outcome did not replicate. Short-allele homozygotes showed more positive treatment outcomes, but with small, non-significant effects. Future studies would benefit from utilising whole genome approaches and large, homogenous samples.